Opinion|Videos|July 9, 2024
Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
Advertisement
Related to this article
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Five Under 5: Top Oncology Videos for the Week of 9/13
3
The OncFive: Top Oncology Articles for the Week of 9/14/2026
4
Olaparib Maintenance Yields Promising Long-Term OS Outcomes in Asian Patients With Platinum-Sensitive, Relapsed Ovarian Cancer
5